GPS Cancer – Personalized molecular decision support for cancer therapy prior to the start of therapy.
GPS Cancer is a unique molecular test that integrates quantitative targeted proteomics by mass spectrometry with whole genome (DNA) and transcriptome (RNA) sequencing of normal and cancerous tissue.
Conducted in CLIA-certified CAP-accredited laboratories, GPS Cancer™ provides oncologists with the most comprehensive molecular profile of a patient's cancer to inform personalized treatment strategies prior to treatment.
For the first time, clinicians will be able to measure the presence of biomarker proteins in a patient's tumour cells at an extremely low quantitative level of atoms per microgram of tumour tissue. Biomarker proteins known to cause drug resistance or indicate drug sensitivity to chemotherapy, monoclonal antibody therapy, hormone therapy, targeted therapy and immunotherapy can now be identified from a patient's tumour tissue (Liquid Tissue™) by the GPS Cancer assay. These discoveries will enable personalized cancer care for patients with actionable data:
- chemotherapy
- monoclonal antibody therapy
- hormone therapy
- targeted therapy
- immunotherapy
The report from GPS Cancer:
- Includes comprehensive genome sequencing of over 20,000 genes and 3 billion base pairs
- includes comprehensive transcriptome sequencing with over 200,000 RNA transcripts
- harnesses the power of quantitative proteomics with mass spectrometry
- compares patients' tumour genome to their normal genome
- the GPS Cancer report is ready in less than 21 days from receipt of the tissue.
The GPS Cancer report offers a list of potential therapy options (if applicable), including targeted therapies and active clinical trials with potential clinical benefit that are approved by the Food and Drug Administration (FDA) and/or therapies to which the cancer may be resistant. The GPS Cancer Report does not recommend treatments and it is the attending physician's responsibility to develop a personalized treatment plan after discussing with the patient the treatment options and potential risks associated with each treatment option.